IMMUNE & TISSUE-REPAIR RESEARCH
Frequently asked questions
Plain-English answers to the questions most commonly asked about Thymosin Alpha-1, KPV, and BPC-157 — what the literature says, and what it does not say.
What is thymosin alpha 1?
Thymosin Alpha-1 is a 28-amino-acid peptide that was first isolated from calf thymus tissue in 1977 [7]. Its drug form — thymalfasin — is sequence-identical to the naturally occurring peptide and is approved as a medicine in more than 35 countries [2]. In research, it is classified as a thymic immunomodulatory peptide: it acts on the immune system's dendritic cells to improve T-cell maturation and the body's capacity to mount and regulate an effective immune response. It is not the same as thymulin (a different thymic peptide) and is entirely unrelated to TB-500 or thymosin-β4.
What does thymosin alpha 1 do?
In research models and clinical studies, Thymosin Alpha-1 signals through Toll-like receptors (TLR2 and TLR9) on dendritic cells, promoting their maturation and their ability to present antigens to T cells. This drives T-cell maturation and Th1 polarisation — the arm of the immune response suited to clearing infections and tumours. A counterbalancing effect through the IDO pathway generates regulatory T cells, tempering hyperinflammation [6]. In practice, this dual action has been studied in sepsis, chronic hepatitis, cancer immunotherapy, and COVID-19.
What is thymosin alpha 1 used for?
In the countries where thymalfasin is approved as a drug, it has been used primarily for chronic hepatitis B and C, as an immunotherapy adjuvant in certain cancers, and as a treatment for sepsis-associated immunoparalysis [2][4]. In research settings (and in the US, where it is not approved for marketing), it has been studied in a wider range of immune-dysfunction contexts. The strongest and most consistent clinical evidence base is in chronic viral hepatitis; the sepsis evidence is more contested, particularly after the null phase-3 TESTS trial of 2025 [1].
Is thymosin alpha 1 FDA-approved?
No. Thymosin Alpha-1 (thymalfasin) is not approved by the US FDA for marketing in the United States. It is approved in more than 35 other countries [2], but US availability is limited to investigational and compounding contexts. Some historical orphan-drug designations exist for specific indications, but these are not marketing approvals. The FDA has not endorsed thymosin alpha-1-related bulk drug substances for pharmacy compounding under 503A.
What is KPV peptide?
KPV is a tripeptide — just three amino acids: Lysine, Proline, Valine (hence the initialism). It corresponds to positions 11-13 of alpha-melanocyte-stimulating hormone (alpha-MSH), its parent molecule. Researchers study it because it appears to retain alpha-MSH's anti-inflammatory properties without the melanogenic (skin-darkening) effects of the full hormone [12]. It is a research chemical with no approved drug or dietary-supplement status; there are no published human clinical trials of KPV.
What does KPV peptide do?
In preclinical research, KPV is taken up into intestinal epithelial cells via the PepT1 transporter (which is upregulated in inflamed intestinal tissue) and then suppresses NF-kB and MAP-kinase inflammatory signalling at nanomolar concentrations, reducing pro-inflammatory cytokine production [10]. In mouse models of colitis, oral or locally delivered KPV reduced disease severity, lowered inflammatory cell infiltration, and preserved intestinal-barrier integrity. All of these findings are in cell cultures and animal models; no equivalent human data exist.
What is KPV peptide used for?
KPV has no approved use. In laboratory research it is studied as a tool for investigating gut mucosal inflammation, particularly as a model for inflammatory bowel disease [11]. Research groups have also explored it in dermatitis, ocular inflammation, and other inflammatory models in animals [12]. Commercial suppliers categorise it strictly as a research chemical for in-vitro and in-vivo laboratory use. Marketing of KPV for human gut health, skin, or general anti-inflammatory purposes outruns the evidence base, which is entirely preclinical.
What is KPV peptide good for?
Based on the published preclinical literature, KPV is good for studying NF-kB-dependent mucosal inflammation in controlled laboratory settings. Whether any of those mechanistic findings translate into benefits in humans is unknown; no clinical trials have been conducted. The compound's fragility as a free tripeptide is also a practical challenge: it is rapidly degraded in biological fluids unless encapsulated in a delivery vehicle [9]. Researchers interested in its potential have focused significant effort on nanoparticle formulation to overcome this limitation before any human application could be meaningfully tested.
What does BPC-157 do in the body?
In animal models — mostly rats — BPC-157 appears to accelerate healing in tendon, gut, muscle, and nerve tissue. The mechanism most consistently demonstrated is pro-angiogenic: the peptide up-regulates the VEGFR2 receptor on blood-vessel endothelial cells and activates the downstream Akt-eNOS signalling cascade, promoting the growth of new blood vessels into damaged tissue [16]. It has also been described as modulating the nitric-oxide system and several neurotransmitter pathways. What it does in the human body specifically is very poorly characterised — only a small number of human pilot studies have been conducted as of 2025 [14].
Is BPC-157 a growth hormone?
No. BPC-157 is not a growth hormone and is not a growth-hormone secretagogue. It is a 15-amino-acid pentadecapeptide derived from a gastric juice protein and has no structural or pharmacological relationship to growth hormone (somatotropin) or to the peptides that stimulate its release (such as GHRH analogues or ghrelin mimetics). It has been shown in tendon-fibroblast models to upregulate growth-hormone-receptor expression, which may partly explain tendon-healing observations in animals, but this is not the same as being a growth hormone or releasing one.
Does BPC-157 work immediately?
In animal models, some acute effects — such as changes in blood-vessel tone related to nitric-oxide signalling — appear relatively quickly, while structural tissue-repair outcomes take longer to manifest. BPC-157 also has a very short elimination half-life: formal pharmacokinetic studies in rats and dogs found it to be under 30 minutes [15]. The implied question about immediate human effects cannot be answered by the literature, as adequate human trials have not been conducted. Anecdotal reports from community users vary widely — some describe noticing changes in joint comfort within one to two weeks; others report nothing. Neither observation constitutes clinical evidence.
Does BPC-157 damage the liver?
There is no evidence from the published literature that BPC-157 damages the liver. The first-in-human intravenous safety pilot (two participants, doses up to 20 mg) found no measurable changes in hepatic biomarkers [13], and the compound's short half-life and breakdown into normal amino-acid metabolites do not suggest a hepatotoxic mechanism. The 2025 narrative review did not identify liver toxicity as a documented concern [14]. That said, the human safety dataset is genuinely tiny — two participants in one pilot study — so the absence of a documented liver effect should not be read as a full safety clearance. Long-term safety in humans is unknown.